PT  - JOURNAL ARTICLE
AU  - Schneeberger, Pierre H.H.
AU  - Kevin Zhang, Chen Yang
AU  - Santilli, Jessica
AU  - Chen, Bo
AU  - Xu, Wei
AU  - Lee, Youngho
AU  - Wijesinha, Zonelle
AU  - Reguera-Nuñez, Elaine
AU  - Yee, Noelle
AU  - Ahmed, Musawir
AU  - Boonstra, Kristen
AU  - Ramendra, Rayoun
AU  - Frankel, Courtney W.
AU  - Palmer, Scott M.
AU  - Todd, Jamie L.
AU  - Martinu, Tereza
AU  - Coburn, Bryan
TI  - Gastroesophageal reflux disease is associated with differences in the allograft microbiome, microbial density and inflammation in lung transplantation
AID  - 10.1101/2021.09.03.21263067
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.03.21263067
4099  - http://medrxiv.org/content/early/2021/09/10/2021.09.03.21263067.short
4100  - http://medrxiv.org/content/early/2021/09/10/2021.09.03.21263067.full
AB  - Rationale Gastroesophageal reflux disease (GERD) may affect lung allograft inflammation and function through its effects on allograft microbial community composition in lung transplant recipients.Objectives Our objective was to compare the allograft microbiota in lung transplant recipients with or without clinically diagnosed GERD in the first post-transplant year, and assess associations between GERD, allograft microbiota, inflammation and acute and chronic lung allograft dysfunction (ALAD/CLAD).Methods 268 bronchoalveolar lavage samples were collected from 75 lung transplant recipients at a single transplant centre every 3 months post-transplant for 1 year. Ten transplant recipients from a separate transplant centre provided samples pre/post-anti-reflux Nissen fundoplication surgery. Microbial community composition and density were measured using 16S rRNA gene sequencing and qPCR, respectively and inflammatory markers and bile acids were quantified.Measurements and Main Results We observed three community composition profiles (labelled community state types, CSTs 1-3). Transplant recipients with GERD were more likely to have CST1, characterized by high bacterial density and relative abundance of the oropharyngeal colonizing genera Prevotella and Veillonella. GERD was associated with more frequent transition to CST1. CST1 was associated with lower per-bacteria inflammatory cytokine levels than the pathogen-dominated CST3. Time-dependant models revealed associations between CST3 and development of ALAD/CLAD. Nissen fundoplication decreased bacterial load and pro-inflammatory cytokines.Conclusion GERD was associated with a high bacterial density, Prevotella/Veillonella dominated CST1. CST3, but not CST1 or GERD, was associated with inflammation and early development of ALAD/CLAD. Nissen fundoplication was associated with decreases in microbial density in BALF samples, especially the CST1-specific genus, Prevotella.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study received financial support from the Canadian Institutes for Health Research (PJT149057, to BC and TM); from the Multi-Organ Transplant Program at the University Health Network (to BC and TM); from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID), Clinical Trials in Organ Transplantation (CTOT-20) Ancillary Study Fund (to TM); from the Comprehensive Research Experience for Medical Students (CREMS) Program (to CYKZ), and from the Cystic Fibrosis Foundation (to BC and TM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Toronto University Health Network Research Ethics Board (REB#15-9698-AE) and the Duke University Internal Review Board (Pro00013378).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSequence data that support the findings of this study have been deposited in the NCBI Short Read Archive with the primary accession code PRJNA754787.